Literature DB >> 20026488

Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.

Serdar Gunaydin1, Kevin McCusker, Tamer Sari, Mehmet Ali Onur, Yaman Zorlutuna.   

Abstract

This prospective randomized study compares novel hyaluronan-based heparin-bonded circuits vs. uncoated controls across EuroSCORE patient risk strata including biomaterial evaluation. Over a two-year period, 90 patients undergoing coronary artery bypass grafting were prospectively randomized to one of the two perfusion protocols: Group 1 was treated with hyaluronan-based heparin-bonded preconnected circuits (Vision HFO-GBS, Gish, CA, USA) and Group 2 with identical uncoated controls. Each group was composed of three subgroups (n=15) with respect to preoperative evaluation of low (EuroSCORE 0-2), medium (3-5) and high (6+) risk patients. Blood samples were collected after induction (T1) and heparinization (T2), 15 min after cardiopulmonary bypass start (T3), before cessation of CPB (T4), 15 min after reversal (T5), and the first postoperative day (T6). In high-risk patients, platelet counts demonstrated significant preservation at T4, T5 and leukocyte counts were lower at T5 in hyaluronan group (P<or=0.05 vs. control). C3a (ng x ml(-1)) levels were significantly lower at T3 (0.2+/-0.04 vs. 0.31+/-0.05), T4 (0.25+/-0.04 vs. 0.51+/-0.05), T5 (0.38+/-0.04 vs. 0.56+/-0.05) and interleukin-6 (pg x ml(-1)) at T4 (91+/-18 vs. 124+/-20), T5 (110+/-20 vs. 220+/-25) in coated group vs. control (P<or=0.05). Protein desorption (microalbumin) on fibers (mg x mm(-3)) was less in hyaluronan vs. control groups (P<or=0.05). Hyaluronan coating reduced platelet adhesion and cell adsorption, and modulated inflammatory response in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026488     DOI: 10.1510/icvts.2009.220756

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  6 in total

1.  Hyaluronan based heparin free coated open and closed extracorporeal circuits for high risk coronary revascularization.

Authors:  Serdar Gunaydin; Halil Ibrahim Ucar; Tanzer Serter; Kevin McCusker; Gokhan Ozcelik; Nevriye Salman; Ali Cem Yorgancioglu
Journal:  J Extra Corpor Technol       Date:  2010-12

Review 2.  VV extracorporeal life support for the Third Millennium: will we need anticoagulation?

Authors:  Danny Eytan; Yuval Bitterman; Gail M Annich
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 3.  Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?

Authors:  Sarah Mahmood; Haris Bilal; Mahvash Zaman; Augustine Tang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-01-06

4.  Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions.

Authors:  Ali Dabbagh; Samira Rajaei; Ayad Bahadori Monfared; Ali Asghar Keramatinia; Korosh Omidi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

5.  Effects of cardiopulmonary bypass on lung nuclear factor-kappa B activity, cytokine release, and pulmonary function in dogs.

Authors:  Gaisheng Yang; Xiaodong Xue; Yanying Chen; Zhihong Song; Zhen Jiang; Kejian Hu
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

6.  Microfluidic cell sorting: Towards improved biocompatibility of extracorporeal lung assist devices.

Authors:  Christian Bleilevens; Jonas Lölsberg; Arne Cinar; Maren Knoben; Oliver Grottke; Rolf Rossaint; Matthias Wessling
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.